1110008L16Rik Inhibitors
Chemical inhibitors of the protein 1110008L16Rik are diverse and target various signaling pathways that regulate its activity. Wortmannin and LY294002 are both inhibitors of phosphoinositide 3-kinases (PI3K), leading to the suppression of the PI3K/AKT signaling pathway. This inhibition can directly decrease the activity of downstream proteins like 1110008L16Rik, which may rely on PI3K/AKT for activation. Similarly, Rapamycin acts upstream of 1110008L16Rik by inhibiting the mammalian target of rapamycin (mTOR) complex, a key modulator of cell growth and protein synthesis. By impeding mTOR signaling, rapamycin can indirectly affect the function of 1110008L16Rik. Other kinase inhibitors, such as U0126 and PD98059, target the MAPK/ERK pathway by inhibiting MEK1/2, leading to a reduction in ERK activation and subsequently impacting proteins like 1110008L16Rik that are downstream of this pathway.
Additionally, SB203580 and SP600125 selectively inhibit p38 MAP kinase and c-Jun N-terminal kinase (JNK), respectively, both of which are part of the MAPK signaling pathways. The inhibition of these kinases by SB203580 and SP600125 can lead to reduced activity of 1110008L16Rik if it is regulated by stress-activated or JNK signaling. Dasatinib and PP2, as tyrosine kinase inhibitors, target different kinases with Dasatinib having a broad-spectrum effect and PP2 being selective for Src family tyrosine kinases. By inhibiting these kinases, the activity of 1110008L16Rik can be suppressed if it is activated by signaling pathways involving these kinases. Lapatinib, which inhibits EGFR and HER2 tyrosine kinase domains, can also impair the function of 1110008L16Rik by blocking downstream signaling. Lastly, Bisindolylmaleimide I and Staurosporine inhibit protein kinase C (PKC) and a broad range of protein kinases, respectively. These inhibitors can decrease the activity of 1110008L16Rik if PKC or other kinases targeted by staurosporine play a role in its activation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3K), which could lead to the inhibition of 1110008L16Rik by reducing the PI3K/AKT signaling pathway, subsequently decreasing the activity of downstream proteins that require PI3K/AKT for activation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits the mammalian target of rapamycin (mTOR) complex, which is crucial for protein synthesis and cell growth. Inhibition of mTOR can lead to decreased activity of downstream proteins like 1110008L16Rik that are regulated by mTOR signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is another inhibitor of PI3K, leading to the inhibition of the PI3K/AKT pathway. This inhibition can suppress the function of proteins such as 1110008L16Rik, which may be activated by this pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which blocks the activation of the MAPK/ERK pathway. By inhibiting this pathway, U0126 can impede the activity of proteins like 1110008L16Rik that are downstream of ERK signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 selectively inhibits p38 MAP kinase, which is involved in cellular responses to stress and cytokines. Inhibition of p38 MAPK can decrease the activity of proteins like 1110008L16Rik that may be regulated by stress-activated pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), part of the MAPK signaling pathway. JNK inhibition can lead to the suppression of proteins like 1110008L16Rik that are potentially regulated by JNK signaling. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor, known to inhibit BCR-ABL and Src family kinases. The inhibition of these kinases can lead to reduced activity of proteins such as 1110008L16Rik that may rely on Src kinase signaling for function. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is a selective inhibitor of Src family tyrosine kinases. By specifically inhibiting Src kinases, PP2 can suppress the activity of proteins like 1110008L16Rik that may be activated by Src kinase signaling. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Lapatinib inhibits the tyrosine kinase domains of EGFR and HER2. By inhibiting these receptors, Lapatinib can reduce the activity of downstream proteins like 1110008L16Rik that may be activated by EGFR/HER2 signaling pathways. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a specific inhibitor of MEK, blocking the activation of ERK. This leads to inhibition of the MEK/ERK pathway and can impair the activity of proteins like 1110008L16Rik that are downstream effectors. | ||||||